Investigational drug · Phase 2
matched to VX-993
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diabetic Peripheral Neuropathic Pain, Acute Pain.
Phase 2Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
6
Any phase or sponsor naming "matched to VX-993"
First trial start
2024
Oct 18, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "matched to VX-993", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Peripheral Neuropathic Pain
- Acute Pain
Approved drugs for the same conditions: Neuropathic pain · Acute pain · Cardiovascular and metabolic · Neurology · Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "matched to VX-993" as an intervention, largest first.
- A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a BunionectomyPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06619847 · 367 participants · Start Oct 29, 2024 · Primary completion May 27, 2025
Drug: VX-993; HB/APAP and 2 more · For: Acute Pain
Sites: Sheffield, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 14 sites in all
- Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral NeuropathyPivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06619860 · 300 participants (planned) · Start Oct 18, 2024 · Primary completion Mar 25, 2027
Drug: VX-993; Pregabalin and 2 more · For: Diabetic Peripheral Neuropathic Pain
Sites: Cullman, Alabama; Bakersfield, California; La Mesa, California · 47 sites in all
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06420765 · 92 participants · Start May 21, 2024 · Primary completion Mar 22, 2025
Drug: VX-150; VX-548 and 2 more · For: Pain
Sites: Manchester, United Kingdom
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06394167 · 88 participants · Start May 9, 2024 · Primary completion Feb 18, 2025
Drug: VX-993; Placebo · For: Pain
Sites: Lenexa, Kansas
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05653323 · 70 participants · Start Dec 14, 2022 · Primary completion Sep 12, 2023
Drug: VX-993; Placebo · For: Pain
Sites: Manchester, United Kingdom
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06226454 · 39 participants · Start Jan 4, 2024 · Primary completion Jun 12, 2024
Drug: VX-993; Placebo · For: Pain
Sites: Salt Lake City, Utah
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Diabetic Peripheral Neuropathic Pain
- HL-1186Phase 36 trials
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. · Postoperative Pain, Moderate to Severe Acute Postoperative Pain, Postherpetic Neuralgia ( PHN )
- matched to PregabalinPhase 32 trials
Vertex Pharmaceuticals · Diabetic Peripheral Neuropathic Pain
- matched to SUZPhase 32 trials
Vertex Pharmaceuticals · Diabetic Peripheral Neuropathic Pain
- LY4065967Phase 23 trials
Eli Lilly · Chronic Pain, Diabetic Peripheral Neuropathic Pain, Osteoarthritis, Knee
- VX-993Phase 22 trials
Vertex Pharmaceuticals · Diabetic Peripheral Neuropathic Pain, Acute Pain
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Vertex Pharmaceuticals.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.